المساهمون: Jean Deschenes, Professor

المصدر: Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study

المؤلفون: Desai, Aparna¹, Pagariya, Ashish^{1, 1}, Rathod, Monika¹, Kayande, Kalyani², Chhajed, Mahavir³, Deokar, Rushali⁴, Rai, Sudhish⁵

المصدر: Research Journal of Pharmacy and Technology 17(5):2035-2039. 2024

المؤلفون: Maxime Le Merdy, Jessica Spires, Ming-Liang Tan, Liang Zhao, Viera Lukacova

المصدر: Pharmaceutics, Vol 16, Iss 7, p 914 (2024)

مصطلحات موضوعية: PBPK, ocular PBPK, ophthalmic suspension, generic, besifloxacin, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.mdpi.com/1999-4923/16/7/914; https://doaj.org/toc/1999-4923

URL الوصول: https://doaj.org/article/8095b13d760d4754a8fd2e1cacdf15b1

المساهمون: Frank A. Bucci, Jr., M.D., Principal Investigator

المصدر: A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification

المساهمون: Frank A. Bucci, Jr., M.D., Principal Investigator

المصدر: Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

المساهمون: Farhad Hafezi, Professor

المصدر: Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis
Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999 Jul;106(7):1313-8.
Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79(3):214-21. Epub 2003 Jul 7.
Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000;78 Suppl 2:211-5.
Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008 Jun;27(5):590-4. doi: 10.1097/ICO.0b013e318169d698.
Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R, Cano M, Dick J, Behrens A. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3402-8. doi: 10.1167/iovs.07-1592. Epub 2008 Apr 11.
Schrier A, Greebel G, Attia H, Trokel S, Smith EF. In vitro antimicrobial efficacy of riboflavin and ultraviolet light on Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa. J Refract Surg. 2009 Sep;25(9):S799-802. doi: 10.3928/1081597X-20090813-07. Epub 2009 Sep 11.
Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010 Dec;29(12):1353-8. doi: 10.1097/ICO.0b013e3181d2de91.
Makdoumi K, Mortensen J, Sorkhabi O, Malmvall BE, Crafoord S. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2012 Jan;250(1):95-102. doi: 10.1007/s00417-011-1754-1. Epub 2011 Aug 27.
Moren H, Malmsjo M, Mortensen J, Ohrstrom A. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea. 2010 Jan;29(1):102-4. doi: 10.1097/ICO.0b013e31819c4e43.
Pot SA, Gallhofer NS, Matheis FL, Voelter-Ratson K, Hafezi F, Spiess BM. Corneal collagen cross-linking as treatment for infectious and noninfectious corneal melting in cats and dogs: results of a prospective, nonrandomized, controlled trial. Vet Ophthalmol. 2014 Jul;17(4):250-60. doi: 10.1111/vop.12090. Epub 2013 Aug 14.
Hafezi F, Hosny M, Shetty R, Knyazer B, Chen S, Wang Q, Hashemi H, Torres-Netto EA; PACK-CXL Working Group. PACK-CXL vs. antimicrobial therapy for bacterial, fungal, and mixed infectious keratitis: a prospective randomized phase 3 trial. Eye Vis (Lond). 2022 Jan 7;9(1):2. doi: 10.1186/s40662-021-00272-0.
Davis SA, Bovelle R, Han G, Kwagyan J. Corneal collagen cross-linking for bacterial infectious keratitis. Cochrane Database Syst Rev. 2020 Jun 17;6(6):CD013001. doi: 10.1002/14651858.CD013001.pub2.

المصدر: Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

المؤلفون: Turki Al Hagbani, Syed Mohd Danish Rizvi, Shazi Shakil, Amr Selim Abu Lila

المصدر: Nanomaterials; Volume 13; Issue 14; Pages: 2083

مصطلحات موضوعية: besifloxacin, eye infection, gold nanoparticles, quercetin, resistant pathogens, synergistic effect

وصف الملف: application/pdf

Relation: Biology and Medicines; https://dx.doi.org/10.3390/nano13142083

الاتاحة: https://doi.org/10.3390/nano13142083

المؤلفون: Blondeau JM, Proskin HM, Sanfilippo CM, DeCory HH

المصدر: Clinical Ophthalmology, Vol Volume 15, Pp 4419-4430 (2021)

مصطلحات موضوعية: pediatric, conjunctivitis, polybacterial, besifloxacin, minimum inhibitory concentration, Ophthalmology, RE1-994

وصف الملف: electronic resource

Relation: https://www.dovepress.com/characterization-of-polybacterial-versus-monobacterial-conjunctivitis--peer-reviewed-fulltext-article-OPTH; https://doaj.org/toc/1177-5483

URL الوصول: https://doaj.org/article/38f55f48aa2548318fb3802e58e6973b

المصدر: Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery

المؤلفون: Pindukuri Chakrapani, Bharath Kumar A, Prakash Reddy PK

مصطلحات موضوعية: Ocular, In situ, Besifloxacin, Ophthalmitis

Relation: https://doi.org/10.5281/zenodo.7561000; https://doi.org/10.5281/zenodo.7561001; oai:zenodo.org:7561001

الاتاحة: https://doi.org/10.5281/zenodo.7561001

المؤلفون: José Izo Santana da Silva de Jesus, Felipe Rebello Lourenço, Kelly Ishida, Thayná Lopes Barreto, Valdir Carlos Avino, Edson dos Santos Neto, Nádia Araci Bou-Chacra

المصدر: Pharmaceutics; Volume 14; Issue 10; Pages: 2221

مصطلحات موضوعية: nanocrystals, conjunctivitis, besifloxacin, Povacoat ®, fluoroquinolones

وصف الملف: application/pdf

Relation: Drug Delivery and Controlled Release; https://dx.doi.org/10.3390/pharmaceutics14102221

الاتاحة: https://doi.org/10.3390/pharmaceutics14102221

المؤلفون: PATIL, JAYASHRI A., B. PATIL, RAVINDRA

المصدر: International Journal of Applied Pharmaceutics; Vol 14, Issue 1 (Jan-Feb), 2022; 148-155 ; 0975-7058

مصطلحات موضوعية: Besifloxacin, Non-erodible ocular insert, Pullulan, PVP, Eudragit RS-100, etc

وصف الملف: application/pdf; text/html

Relation: https://innovareacademics.in/journals/index.php/ijap/article/view/43058/25883; https://innovareacademics.in/journals/index.php/ijap/article/view/43058/25952; https://innovareacademics.in/journals/index.php/ijap/article/view/43058

الاتاحة: https://innovareacademics.in/journals/index.php/ijap/article/view/43058

المؤلفون: Bausch & Lomb Incorporated

المصدر: A Prospective, Double-Blinded, Parallel-Group, Randomized Study to Assess the Safety and Efficacy of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children

المؤلفون: Jun-Jie Wang, Xin-Yi Gao, Hong-Zhuo Li, Shan-Shuang Du

المصدر: International Journal of Ophthalmology, Vol 12, Iss 12, Pp 1898-1907 (2019)

مصطلحات موضوعية: besifloxacin, acute bacterial conjunctivitis, meta-analysis, randomized controlled trials, Ophthalmology, RE1-994

وصف الملف: electronic resource

Relation: http://www.ijo.cn/en_publish/2019/12/20191213.pdf; https://doaj.org/toc/2222-3959; https://doaj.org/toc/2227-4898

URL الوصول: https://doaj.org/article/dc90f749f59145a29e81e6f7da0cf9d3

المؤلفون: Barry A. Schechter, John D. Sheppard, Christine M. Sanfilippo, Heleen H. DeCory, Penny A. Asbell

المصدر: Ophthalmology and Therapy, Vol 9, Iss 1, Pp 159-173 (2019)

مصطلحات موضوعية: Antibiotic resistance, Besifloxacin, Molecular characteristics, Ocular surface infections, Staphylococci, Ophthalmology, RE1-994

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1007/s40123-019-00223-y; https://doaj.org/toc/2193-8245; https://doaj.org/toc/2193-6528

URL الوصول: https://doaj.org/article/35f34f972f534a8089eb351ce073e6cf

المؤلفون: SCRI Development Innovations, LLC, Bausch & Lomb Incorporated

المصدر: A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers.

المصدر: A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. PLoS One. 2020 Aug 25;15(8):e0237603. doi: 10.1371/journal.pone.0237603. eCollection 2020.
Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.
Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009 Mar;31(3):514-26. doi: 10.1016/j.clinthera.2009.03.010.

المصدر: A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.
DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. PLoS One. 2020 Aug 25;15(8):e0237603. doi: 10.1371/journal.pone.0237603. eCollection 2020.
Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.
Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009 May;25(5):1159-69. doi: 10.1185/03007990902837919.

المصدر: A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis
DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. PLoS One. 2020 Aug 25;15(8):e0237603. doi: 10.1371/journal.pone.0237603. eCollection 2020.
Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.